Holen Sie sich die Stockscreener-App
0.1753
0.17%
-0.0003
Handel nachbörslich:
.17
-0.0053
-3.02%
Gossamer Bio Inc Aktie (GOSS) Neueste Nachrichten
Price to earnings forward of Gossamer Bio, Inc. – NASDAQ:GOSS - tradingview.com
Biotech Gossamer Bio (NASDAQ: GOSS) markets $125M more in private securities - Stock Titan
Gossamer Bio to Present at Cantor Global Healthcare Conference - finance.yahoo.com
Gossamer Bio seeks nod for 1.6B-share issuance | GOSS SEC FilingForm PRE 14A - Stock Titan
Gossamer Bio Stock (GOSS) Opinions on Phase Advancement Catalysts - Moomoo
H.C. Wainwright reiterates Gossamer Bio stock rating on NDA progress By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Gossamer Bio stock rating on NDA progress - Investing.com
Gossamer Bio (NASDAQ: GOSS) ties CFO’s 5.8M options to seralutinib FDA decision - Stock Titan
Gossamer Bio (NASDAQ: GOSS) ties CCO options to FDA drug decision - Stock Titan
GOSS 4-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS - Eastern Progress
Gossamer Bio (NASDAQ: GOSS) has 6% of its stock under D. E. Shaw’s reported influence - Stock Titan
Gossamer Bio Slides as $250M Financing Hinges on FDA Milestones - Sahm
Gossamer Bio (NASDAQ:GOSS) Funding Move Signals Biotech Shift - Kalkine Media
Gossamer Bio Secures Up To $250 Million To Fund Seralutinib Through Potential FDA Approval - Pulse 2.0
Latham Advises Gossamer Bio on Structured Private Placement - Latham & Watkins LLP
Latham Advises Gossamer Bio on Up to US$250 Million Structured Private Placement, Including US$150 Million of Committed Capital - Legal Desire
Gossamer Bio Slips as $250M Financing Hinges on FDA ApprovalGossamer Bio (NASDAQ:GOSS) - Benzinga
Gossamer Bio (GOSS) Raises $250M in Private Placement Amid Chall - GuruFocus
Gossamer Bio Secures Up to $250 Million Private Placement to Fund Seralutinib Through Potential FDA Approval - Yahoo Finance
Gossamer Bio Secures Up to $250M to Advance Seralutinib Toward FDA Approval - citybiz
$Gossamer Bio (GOSS.US)$ yessir 🦁 mode still early - Moomoo
Gossamer Bio (GOSS) Raises $250M in Private Placement Amid Challenging Valuation Landscape - GuruFocus
Gossamer Bio Agrees to Up to $250 Million Private Placement; Shares Rise Pre-Bell - marketscreener.com
Gossamer Bio secures up to $250m in milestone-based financing - Investing.com
$Gossamer Bio (GOSS.US)$ @traderslink_this_guy@TradersLink__ we never lacking 🤷♂️ 😉 - Moomoo
Gossamer Bio Lines Up Up To $250 Million Private Placement With Milestone-Triggered Warrants - TradingView
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval - Yahoo Finance
Gossamer Bio, Inc. announced that it expects to receive $250 million in funding - marketscreener.com
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits
Revenue per share of Gossamer Bio, Inc. – HAM:4GB - TradingView
Gossamer Bio achieves exceptional financial eff... - Pluang
Gossamer Bio (GOSS) Stock Sees Fair Value Cut As Analysts Split On Seralutinib - Yahoo Finance
GOSS Maintained by Piper Sandler -- Price Target Lowered to $4.0 - GuruFocus
Gossamer Bio Inc (GOSS) News, Articles, Events & Latest Updates - Stocktwits
GOSS|Gossamer Bio Inc|Price:0.154|Chg%:-0.016 - TradingKey
Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update - BioSpace
$Gossamer Bio (GOSS.US)$ This is the bottom - Moomoo
Gossamer Bio: Q2 Earnings Snapshot - AOL.com
Gossamer Bio Q2 Results: EPS beats estimate, sales up 78% vs view - scanx.trade
Is Gossamer Bio Inc (GOSS) Undervalued After Q2 Earnings Beat? G - GuruFocus
Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Gossamer Bio, Inc. 2026: Revenue $9.24M, Net income $16.9M, EPS ($0.08) — 10-Q Summary - TradingView
Gossamer Bio reports Q2 2026 net income of $16.9M; cash $57.0M, NDA submission for seralutinib on track - TradingView
Gossamer Bio (GOSS) cuts debt but flags going concern and liquidity strain - Stock Titan
Gossamer Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
Gossamer Bio Inc (GOSS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gossamer Bio Company Profile & Introduction - Moomoo
Gossamer Bio Inc (GOSS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm - Morningstar
Bronstein, Gewirtz & Grossman, LLC Is Investigating Gossamer Bio - The National Law Review
Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Gro - The National Law Review
gossamer bio inc. Earnings dates - RTTNews
Gossamer Bio Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
BlackRock (GOSS) discloses 4.89M-share, 1% beneficial stake in Gossamer Bio - Stock Titan
$Gossamer Bio (GOSS.US)$ call me crazy but atlease you calling... - Moomoo
GOSS Upgraded by Leerink Partners -- Rating Changed to Outperform - GuruFocus
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Leerink Partners Upgrades Gossamer Bio to Outperform From Market Perform, $1 Price Target - marketscreener.com
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):